A. Weinstein

发表

Using Transcriptional Signatures to Find Cancer Drivers with LURE

Joshua M. Stuart, Christopher K. Wong, D. Haan, 2019, bioRxiv.

Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.

W. Powlis, D. Nelson, W. Curran, 1993, International journal of radiation oncology, biology, physics.

Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative.

P. Engstrom, Steven J. Cohen, E. Sigurdson, 2011, Clinical colorectal cancer.

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

Joshua M. Stuart, M. Gleave, F. Feng, 2020, Clinical Cancer Research.

Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative.

Steven J. Cohen, R. Swaby, L. Goldstein, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Pulmonary toxicity of carmustine in patients treated for malignant glioma.

D. Nelson, M. Diener-West, E. Pakuris, 1986, Cancer treatment reports.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Joshua M. Stuart, Christopher K. Wong, M. Rubin, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

Joel A. Yates, Christopher K. Wong, M. Gleave, 2022, Nature Communications.

Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.

Joshua M. Stuart, Christopher K. Wong, M. Gleave, 2020, Urologic oncology.

Misonidazole and radiotherapy to treat malignant glioma: a phase II trial of the radiation therapy oncology group.

R. Goodman, A. Weinstein, M. Richter, 1981, International journal of radiation oncology, biology, physics.

Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures

David Haussler, Holly C Beale, Lauren M Sanders, 2020, PLoS Comput. Biol..

TumorMap: Exploring the Molecular Similarities of Cancer Samples in an Interactive Portal.

David Haussler, Theodore C Goldstein, Sofie R Salama, 2017, Cancer research.

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study

D. Schoenfeld, J. Horton, S. Kramer, 1983, Cancer.

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

Joshua M. Stuart, M. Gleave, F. Feng, 2020, Proceedings of the National Academy of Sciences.

A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.

D. Nelson, W. Sause, D. Schoenfeld, 1983, International journal of radiation oncology, biology, physics.

Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate

M. Gleave, L. True, F. Feng, 2020 .

Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02

D. Nelson, L. Gaspar, W. Curran, 1996, Cancer.

Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer

Joshua M. Stuart, E. Small, Jiaoti Huang, 2020, Prostate Cancer and Prostatic Diseases.

Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer

Joshua M. Stuart, F. Feng, E. Small, 2020, Prostate Cancer and Prostatic Diseases.

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

D. Nelson, W. Curran, C. Scott, 1993, Journal of the National Cancer Institute.

Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials

W. Powlis, D. Nelson, W. Curran, 1992, Journal of Neuro-Oncology.

Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.

W. Curran, T. Phillips, J. Schwade, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of accelerated hyperfractionated radiation therapy and bis‐chlorethyl nitrosourea for malignant glioma. A preliminary report of radiation therapy oncology group 83–02

W. Powlis, D. Nelson, W. Curran, 1992, Cancer.

Misonidazole and radiotherapy (RT) in the treatment of malignant glioma: A phase II trial

R. Goodman, A. Weinstein, M. Richter, 1979 .

Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials.

D. Nelson, W. Curran, P. Rubin, 1993, International journal of radiation oncology, biology, physics.

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer

Xiaolin Zhu, M. Gleave, A. Wyatt, 2023, Cancer research.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Joshua M. Stuart, Christopher K. Wong, M. Rubin, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The DNA methylation landscape of advanced prostate cancer

Joshua M. Stuart, D. Spratt, E. Small, 2020 .